Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 in mild COVID-19
NCT04730427Phase 1Terminated
- Sponsor
- Genexine
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing GX-I7 with Placebo (2 arms). Primary endpoints: Incidence rate, characteristics, and severity of adverse reactions at 52 weeks, Shift from baseline of vital sign at 52 weeks and 4 more. Started Mar 2021; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04730427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730427.